Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Adma Biologics (ADMA) over the last 8 years, with Q3 2025 value amounting to $2.6 million.

  • Adma Biologics' Other Accumulated Expenses fell 2271.49% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2271.49%. This contributed to the annual value of $2.0 million for FY2024, which is 1560.25% down from last year.
  • Per Adma Biologics' latest filing, its Other Accumulated Expenses stood at $2.6 million for Q3 2025, which was down 2271.49% from $17.5 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Other Accumulated Expenses ranged from a high of $17.5 million in Q2 2025 and a low of $981721.0 during Q4 2021
  • Moreover, its 5-year median value for Other Accumulated Expenses was $2.2 million (2023), whereas its average is $3.1 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 3389.38% in 2023, then surged by 66313.26% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Other Accumulated Expenses stood at $981721.0 in 2021, then soared by 82.94% to $1.8 million in 2022, then soared by 31.68% to $2.4 million in 2023, then decreased by 15.6% to $2.0 million in 2024, then grew by 28.36% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $17.5 million for Q2 2025, and $2.0 million during Q1 2025.